Medicine
Cholestyramine 4 g/9 g powder for oral suspension
Cholestyramine 4 g/9 g powder for oral suspension is a generic prescription medicine for oral use, made by 10 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Cholestyramine
- Brand
- Sold under the generic name
- Strength
- 4 g/9 g
- Dosage form
- Powder for oral suspension
- Route
- Oral
- Packs
- 378 g, 60 pouches, 60 packets and 22 more
- Manufacturers
- Zydus LifesciencesIndiaAjanta PharmaIndiaMacleods PharmaceuticalsIndiaMicro LabsIndiaEpic PharmaBlu PharmaceuticalsPar HealthAiPing PharmaceuticalBryant Ranch PrepackPrecision Dose
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C10AC01 Cholestyramine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 September 2005
- Identifiers
- RxCUI 848943, 1801279DailyMed set ID d02eca8c-18d4-4b11-bb16-08748543b04d, c65e556a-3b6a-4466-a7ce-5b24103ed8ad, a0b64dfe-49bc-45d7-9281-9e9d6e296c40 +11NDC 42806-265, 42806-267, 27241-134 +11Application ANDA074557, ANDA211119, ANDA077204 +5
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 378 g in 1 can | 68382-528-42 | Zydus LifesciencesIndia | 1 August 2018 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 68382-528-60 | Zydus LifesciencesIndia | 1 August 2018 |
| 378 g in 1 can | 70771-1105-1 | Zydus LifesciencesIndia | 1 August 2018 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 70771-1105-2 | Zydus LifesciencesIndia | 1 August 2018 |
| 60 packet in 1 carton / 9 g in 1 packet | 27241-134-36 | Ajanta PharmaIndia | 6 April 2020 |
| 378 g in 1 bottle | 27241-134-51 | Ajanta PharmaIndia | 6 April 2020 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 33342-293-70 | Macleods PharmaceuticalsIndia | 21 November 2024 |
| 378 g in 1 jar | 33342-293-71 | Macleods PharmaceuticalsIndia | 21 November 2024 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 42571-508-29 | Micro LabsIndia | 1 April 2026 |
| 9 g in 1 pouch | 42806-265-98 | Epic Pharma | 15 December 2021 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 42806-266-95 | Epic Pharma | 15 December 2021 |
| 378 g in 1 jar | 42806-267-93 | Epic Pharma | 29 September 2023 |
| 378 g in 1 can | 42806-267-97 | Epic Pharma | 15 December 2021 |
| 378 g in 1 jar | 11788-150-17 | AiPing Pharmaceutical | 1 September 2026 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 11788-150-60 | AiPing Pharmaceutical | 1 September 2026 |
| 378 g in 1 jar | 24658-266-93 | Blu Pharmaceuticals | 29 April 2024 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 24658-266-95 | Blu Pharmaceuticals | 14 March 2023 |
| 378 g in 1 can | 24658-266-97 | Blu Pharmaceuticals | 14 March 2023 |
| 378 g in 1 bottle | 49884-465-51 | Par Health | 24 April 2026 |
| 60 packet in 1 carton / 9 g in 1 packet | 49884-465-65 | Par Health | 15 September 2005 |
| 378 g in 1 can | 49884-465-66 | Par Health | 15 September 2005 |
| 378 g in 1 can | 63629-2164-1 | Bryant Ranch Prepack | 15 September 2005 |
| 378 g in 1 can | 72162-1504-2 | Bryant Ranch Prepack | 26 September 2023 |
| 348.6 g in 1 can | 68094-806-10 | Precision Dose | 25 April 2024 |
| 60 pouch in 1 carton / 9 g in 1 pouch | 68094-806-20 | Precision Dose | 25 April 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 3 August 1973 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Cholestyramine 4 g/9 g powder for oral suspension.
Other strengths and forms of Cholestyramine
Clinical summary
Cholestyramine is a bile acid sequestrant indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. MedsAcross supplies Cholestyramine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CholestyramineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CHOLESTYRAMINE prescribing information (Zydus Lifesciences) · U.S. National Library of Medicine, DailyMed
Need Cholestyramine 4 g/9 g powder for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.